Kelly, W. K., Appleman, L. J., Lin, C.-C., Armstrong, A. J., Fischer, S. C., Pook, D. W., … Danila, D. C. (2024). 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study. In Annals of Oncology (Vol. 35, pp. S963–S964). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.1679

Kelly, W. K., L. J. Appleman, C. -. C. Lin, A. J. Armstrong, S. C. Fischer, D. W. Pook, J. L. Perez Gracia, et al. “1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study.” In Annals of Oncology, 35:S963–64. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.1679.

Kelly WK, Appleman LJ, Lin C-C, Armstrong AJ, Fischer SC, Pook DW, et al. 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study. In: Annals of Oncology. Elsevier BV; 2024. p. S963–4.

Kelly, W. K., et al. “1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S963–64. Crossref, doi:10.1016/j.annonc.2024.08.1679.

Kelly WK, Appleman LJ, Lin C-C, Armstrong AJ, Fischer SC, Pook DW, Perez Gracia JL, Lee JL, Berthold DR, Ward PJ, Castellano Gauna DE, Horvath LG, Kim M, Matsubara N, Sumey C, Shabooti M, Yang Z, Connarn J, Stieglmaier J, Danila DC. 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study. Annals of Oncology. Elsevier BV; 2024. p. S963–S964.